bluebird bio, Inc. (NASDAQ:BLUE) – Analysts at Jefferies Group boosted their FY2021 earnings per share (EPS) estimates for shares of bluebird bio in a research report issued on Wednesday. Jefferies Group analyst B. Amin now forecasts that the biotechnology company will post earnings of $4.38 per share for the year, up from their previous estimate of $4.34. Jefferies Group has a “Hold” rating and a $126.00 price objective on the stock.

Several other research firms have also recently weighed in on BLUE. Evercore ISI initiated coverage on shares of bluebird bio in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $102.00 price objective for the company. Maxim Group restated a “buy” rating and set a $170.00 price objective (up previously from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Barclays PLC started coverage on shares of bluebird bio in a report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 price objective for the company. Wedbush restated an “outperform” rating and set a $135.00 price objective (up previously from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $162.00 price target (up previously from $145.00) on shares of bluebird bio in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $129.25.

TRADEMARK VIOLATION WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/bluebird-bio-inc-blue-forecasted-to-post-fy2021-earnings-of-4-38-per-share.html.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company’s revenue was up 397.4% on a year-over-year basis. During the same quarter last year, the business earned ($2.07) earnings per share.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Daiwa Securities Group Inc. grew its position in bluebird bio by 25.9% in the 3rd quarter. Daiwa Securities Group Inc. now owns 21,263 shares of the biotechnology company’s stock valued at $2,920,000 after purchasing an additional 4,368 shares during the period. Prudential Financial Inc. grew its position in bluebird bio by 12.6% in the 3rd quarter. Prudential Financial Inc. now owns 4,372 shares of the biotechnology company’s stock valued at $600,000 after purchasing an additional 490 shares during the period. American Century Companies Inc. acquired a new stake in bluebird bio in the 3rd quarter valued at $31,170,000. State of Wisconsin Investment Board grew its position in bluebird bio by 42.0% in the 3rd quarter. State of Wisconsin Investment Board now owns 44,032 shares of the biotechnology company’s stock valued at $6,048,000 after purchasing an additional 13,032 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its position in bluebird bio by 7.4% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 24,670 shares of the biotechnology company’s stock valued at $3,388,000 after purchasing an additional 1,690 shares during the period.

In related news, insider Eric Sullivan sold 861 shares of bluebird bio stock in a transaction on Friday, August 4th. The shares were sold at an average price of $93.83, for a total value of $80,787.63. Following the completion of the sale, the insider now owns 5,924 shares of the company’s stock, valued at approximately $555,848.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Lynch sold 500 shares of bluebird bio stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the sale, the director now directly owns 3,300 shares of the company’s stock, valued at approximately $396,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 150,002 shares of company stock valued at $18,840,335. Insiders own 3.90% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.